Lilly closes AtaiBeckley acquisition, adding an experimental depression therapy

Eli Lilly and Company said on Sept. 11, 2026, that it completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company whose lead investigational program, BPL-003, targets treatment-resistant depression ^[1]. The Indianapolis-based drugmaker announced the close in a news release issued the same day ^[1][2].

AtaiBeckley develops what Lilly describes as rapid-acting neuroplastogens for mental health conditions, and BPL-003 is the most advanced program in that pipeline ^[1]. Both companies are described as clinical-stage in this work, meaning no AtaiBeckley product is approved for sale and none is available by prescription ^[1]. Lilly said the acquisition is intended to advance therapies for treatment-resistant depression and other mental health conditions ^[1].

Financial terms of the transaction were not disclosed in the announcement ^[1]. The release also does not explain how neuroplastogens work or how they would differ from existing antidepressants; those details have not been reported ^[1].

Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, said treatment-resistant depression "persists even after multiple treatment attempts, leaving millions of people still searching for relief" ^[1]. She said AtaiBeckley's neuroplastogens "have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing" ^[1]. The release included no clinical trial results for BPL-003 and presented no efficacy or safety data ^[1].

AtaiBeckley shareholders approved the transaction at a special meeting held before the closing, Lilly said ^[1]. Lilly's own cautionary language states that there is no guarantee the company will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed, or that it will yield commercially successful products ^[1][2]. Lilly describes its research as spanning diabetes care, obesity and its long-term effects, Alzheimer's disease, immune system disorders and cancer ^[1].

Why it matters for patients

BPL-003 is not an approved medicine. Nothing in the announcement says the Food and Drug Administration has reviewed or cleared it, and people with treatment-resistant depression cannot obtain it outside a clinical trial ^[1]. Lilly did not say when further trials might begin, when it might seek approval, or what a treatment would cost ^[1].

The deal does not change any medicine that is already on the market. It covers a separate area of research from the GLP-1 and obesity medicines Lilly sells, and the announcement says nothing about supply, insurance coverage or prescribing for those products ^[1].

Treatment-resistant depression is described in the release as depression that persists after multiple treatment attempts ^[1]. The release does not say how many treatments, or which ones, define that category; that detail has not been disclosed ^[1]. It also does not say how many people in the United States would fall into it.

For patients who follow Lilly's pipeline, this is an early-stage addition. Lilly is buying a clinical-stage company with an investigational program, not a marketed product or an approved therapy ^[1].

What happens next

Lilly says it is "committed to advancing" the AtaiBeckley programs for patients who need more options, but the release sets no dates for further studies, regulatory submissions or a possible launch ^[1]. No milestone schedule or expected timeline has been disclosed ^[1].